Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties |
| |
| Authors: | Sergeeva Maria V Zhou Yuefen Bartkowski Darian M Nolan Thomas G Norris Daniel A Okamoto Ellen Kirkovsky Leo Kamran Ruhi Lebrun Laurie A Tsan Mei Patel Rupal Shah Amit M Lardy Matthew Gobbi Alberto Li Lian-Sheng Zhao Jingjing Bertolini Thomas Stankovic Nebojsa Sun Zhongxiang Murphy Douglas E Webber Stephen E Dragovich Peter S |
| |
| Institution: | Anadys Pharmaceuticals, Inc., Medicinal Chemistry, 3115 Merryfield Row, San Diego, CA 92121, USA. |
| |
| Abstract: | 5-Hydroxy-3(2H)-pyridazinone derivatives were investigated as potent inhibitors of genotype 1 HCV NS5B polymerase focusing on the optimization of their drug metabolism and pharmacokinetics (DMPK) profiles. This investigation led to the discovery of potent inhibitors with improved DMPK properties. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
